Epigenetic Modifier MLL4 Shows Dual Role: Cancer Driver in Leukemia, Suppressor in Solid Tumors

Researchers have discovered that the epigenetic modifier MLL4 plays a paradoxical role in cancer development, acting as a disease driver in certain leukemias while simultaneously suppressing solid tumors. This unusual dual function challenges conventional understanding of how epigenetic regulators contribute to cancer progression. The finding suggests that MLL4-targeted therapies must be carefully tailored based on cancer type to avoid unintended consequences. Understanding these context-dependent mechanisms could lead to more precise and effective cancer treatments for Puerto Rican patients and populations worldwide.